Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue.

Cassoni P, Papotti M, Catapano F, Ghè C, Deghenghi R, Ghigo E, Muccioli G

The Journal of endocrinology1 Apr 2000Cited by 56 (Europe PMC)

PMID10750044DOI10.1677/joe.0.1650139PepBankPUB-10750044

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

12 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In non-tumoral human thyroid membranes, MK 0677 completely displaced the radioligand.
In plain wordsIn lab tests, MK 0677 fully displaced the labeled ligand from normal human thyroid binding sites.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseRadioligand displacement
Study
humann: not reported in source
non-tumoral thyroid membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Both peptidyl (Tyr-Ala-hexarelin, hexarelin, growth hormone releasing peptide (GHRP6) and non-peptidyl (MK 0677) GHSs completely displaced the radioligand from binding sites of non-tumoral thyroid gland, but MK 0677 was significantly less potent.
1 context sentence(design, population, supporting numbers)
Summary · context
The presence of specific receptors for synthetic growth hormone secretagogues (GHSs) has been investigated in non-tumoral and neoplastic human thyroid tissue using a radio-iodinated peptidyl GHS ((125)I-labelled Tyr-Ala-hexarelin) as ligand.
Report a problemFND-1075004407
02LabEx vivo tissueActivity measurement
In non-tumoral human thyroid membranes, MK 0677 was significantly less potent at radioligand displacement than peptidyl GHSs.
In plain wordsIn lab tests, MK 0677 displaced the labeled ligand less potently than peptide secretagogues in normal human thyroid tissue.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseDisplacement potency
Study
humann: not reported in source
non-tumoral thyroid membranes
Comparator
Peptidyl GHSs
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Both peptidyl (Tyr-Ala-hexarelin, hexarelin, growth hormone releasing peptide (GHRP6) and non-peptidyl (MK 0677) GHSs completely displaced the radioligand from binding sites of non-tumoral thyroid gland, but MK 0677 was significantly less potent.
1 context sentence(design, population, supporting numbers)
Summary · context
The presence of specific receptors for synthetic growth hormone secretagogues (GHSs) has been investigated in non-tumoral and neoplastic human thyroid tissue using a radio-iodinated peptidyl GHS ((125)I-labelled Tyr-Ala-hexarelin) as ligand.
Report a problemFND-1075004408
03LabEx vivo tissueActivity measurement
In non-tumoral human thyroid membranes, MK 0677 had an IC(50) of (1. 5+/-0.4)x 10(-7) mol/l.
In plain wordsIn lab tests, the study measured MK 0677 binding potency in normal human thyroid tissue.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableBinding IC(50)
Study
humann: not reported in source
non-tumoral thyroid membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
and only (1. 5+/-0.4)x 10(-7) mol/l for MK 0677.
1 context sentence(design, population, supporting numbers)
Summary · context
The presence of specific receptors for synthetic growth hormone secretagogues (GHSs) has been investigated in non-tumoral and neoplastic human thyroid tissue using a radio-iodinated peptidyl GHS ((125)I-labelled Tyr-Ala-hexarelin) as ligand.
Report a problemFND-1075004409
04LabEx vivo tissueActivity measurement
In human neoplastic thyroid tissue, MK 0677 binding IC(50) values were similar to those in non-tumoral thyroid tissue.
In plain wordsIn lab tests, MK 0677 had similar binding potency in cancerous and normal human thyroid tissue.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeBinding IC(50) in neoplastic tissue
Study
humann: not reported in source
neoplastic thyroid tissue
Comparator
Non-tumoral thyroid tissue
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Similar IC(50) values were found in neoplastic thyroid tissue.
2 context sentences(design, population, supporting numbers)
Summary · context
and only (1. 5+/-0.4)x 10(-7) mol/l for MK 0677.
Summary · context
The presence of specific receptors for synthetic growth hormone secretagogues (GHSs) has been investigated in non-tumoral and neoplastic human thyroid tissue using a radio-iodinated peptidyl GHS ((125)I-labelled Tyr-Ala-hexarelin) as ligand.
Report a problemFND-1075004410
05LabIn vitro (cells)Activity measurement
In NPA human follicular thyroid carcinoma cells, GHRP‑6 inhibited serum-stimulated thymidine incorporation at concentrations close to its binding affinity.
In plain wordsIn thyroid cancer cells, GHRP‑6 reduced DNA synthesis stimulated by serum.
Peptide
GHRP-6
Outcome
DecreaseSerum-stimulated thymidine incorporation
Study
humann: not reported in source
NPA follicular thyroid carcinoma cells
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Tyr-Ala-hexarelin, GHRP6 and MK 0677 were able to inhibit serum-stimulated [(3)H]thymidine incorporation in NPA cells at concentrations close to their binding affinity.
Report a problemFND-1075004403
06LabIn vitro (cells)Activity measurement
In three human follicular thyroid carcinoma cell lines, GHRP‑6 significantly inhibited cell proliferation at 24 h in all lines and at 96 h in NPA cells only.
In plain wordsIn thyroid cancer cell lines, GHRP‑6 slowed cell growth, early in all three lines and late in one.
Peptide
GHRP-6
Outcome
DecreaseCell proliferation
Study
humann: not reported in source
NPA, WRO and ARO follicular thyroid carcinoma cells
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Source sentences
Summary
These substances also caused a significant inhibition of cell proliferation, which was evident at the earliest time of treatment (24 h) in all the cell lines, and at the latest time (96 h) in NPA cells only.
1 context sentence(design, population, supporting numbers)
Summary · context
Tyr-Ala-hexarelin, GHRP6 and MK 0677 were able to inhibit serum-stimulated [(3)H]thymidine incorporation in NPA cells at concentrations close to their binding affinity.
Report a problemFND-1075004404
07LabIn vitro (cells)Activity measurement
In NPA human thyroid carcinoma cells, MK 0677 inhibited serum-stimulated thymidine incorporation at concentrations near its binding affinity.
In plain wordsIn cells, MK 0677 reduced serum-stimulated DNA synthesis in NPA thyroid cancer cells.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseSerum-stimulated thymidine incorporation
Study
humann: not reported in source
NPA thyroid carcinoma cells
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Tyr-Ala-hexarelin, GHRP6 and MK 0677 were able to inhibit serum-stimulated [(3)H]thymidine incorporation in NPA cells at concentrations close to their binding affinity.
1 context sentence(design, population, supporting numbers)
Summary · context
The presence of specific receptors for synthetic growth hormone secretagogues (GHSs) has been investigated in non-tumoral and neoplastic human thyroid tissue using a radio-iodinated peptidyl GHS ((125)I-labelled Tyr-Ala-hexarelin) as ligand.
Report a problemFND-1075004411
08LabIn vitro (cells)Efficacy outcome
In NPA, WRO and ARO human thyroid carcinoma cells, MK 0677 significantly inhibited proliferation at 24 h.
In plain wordsIn cells, MK 0677 reduced growth of all tested human thyroid cancer cell lines at 24 h.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseCell proliferation at early treatment
Study
humann: not reported in source
NPA, WRO and ARO thyroid carcinoma cells
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · 24 hAs given in this study (human).
Source sentences
Summary
These substances also caused a significant inhibition of cell proliferation, which was evident at the earliest time of treatment (24 h) in all the cell lines, and at the latest time (96 h) in NPA cells only.
3 context sentences(design, population, supporting numbers)
Summary · context
Tyr-Ala-hexarelin, GHRP6 and MK 0677 were able to inhibit serum-stimulated [(3)H]thymidine incorporation in NPA cells at concentrations close to their binding affinity.
Summary · context
On the basis of this evidence, we investigated the effects of some GHS on the proliferation of three different human follicular thyroid carcinoma cell lines (NPA, WRO and ARO) in which the presence of specific GHS receptors was also demonstrated.
Summary · context
The presence of specific receptors for synthetic growth hormone secretagogues (GHSs) has been investigated in non-tumoral and neoplastic human thyroid tissue using a radio-iodinated peptidyl GHS ((125)I-labelled Tyr-Ala-hexarelin) as ligand.
Report a problemFND-1075004412
09LabIn vitro (cells)Efficacy outcome
In human thyroid carcinoma cells, MK 0677 proliferation inhibition persisted at 96 h only in NPA cells.
In plain wordsIn cells, MK 0677 still reduced growth at 96 h only in the NPA thyroid cancer line.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseCell proliferation at late treatment
Study
humann: not reported in source
NPA thyroid carcinoma cells
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · 96 hAs given in this study (human).
Source sentences
Summary
These substances also caused a significant inhibition of cell proliferation, which was evident at the earliest time of treatment (24 h) in all the cell lines, and at the latest time (96 h) in NPA cells only.
3 context sentences(design, population, supporting numbers)
Summary · context
Tyr-Ala-hexarelin, GHRP6 and MK 0677 were able to inhibit serum-stimulated [(3)H]thymidine incorporation in NPA cells at concentrations close to their binding affinity.
Summary · context
On the basis of this evidence, we investigated the effects of some GHS on the proliferation of three different human follicular thyroid carcinoma cell lines (NPA, WRO and ARO) in which the presence of specific GHS receptors was also demonstrated.
Summary · context
The presence of specific receptors for synthetic growth hormone secretagogues (GHSs) has been investigated in non-tumoral and neoplastic human thyroid tissue using a radio-iodinated peptidyl GHS ((125)I-labelled Tyr-Ala-hexarelin) as ligand.
Report a problemFND-1075004413
10LabIn vitro (cells)Efficacy outcome
In WRO and ARO human thyroid carcinoma cells, MK 0677 did not significantly inhibit proliferation at 96 h.
In plain wordsIn cells, MK 0677 did not significantly reduce WRO and ARO thyroid cancer cell growth at 96 h.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeCell proliferation at late treatment in WRO and ARO cells
Study
humann: not reported in source
WRO and ARO thyroid carcinoma cells
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · 96 hAs given in this study (human).
Source sentences
Summary
These substances also caused a significant inhibition of cell proliferation, which was evident at the earliest time of treatment (24 h) in all the cell lines, and at the latest time (96 h) in NPA cells only.
2 context sentences(design, population, supporting numbers)
Summary · context
Tyr-Ala-hexarelin, GHRP6 and MK 0677 were able to inhibit serum-stimulated [(3)H]thymidine incorporation in NPA cells at concentrations close to their binding affinity.
Summary · context
On the basis of this evidence, we investigated the effects of some GHS on the proliferation of three different human follicular thyroid carcinoma cell lines (NPA, WRO and ARO) in which the presence of specific GHS receptors was also demonstrated.
Report a problemFND-1075004414
11LabIn vitro (cell-free)Activity measurement
In membranes of human non-tumoral thyroid gland, GHRP‑6 completely displaced the radioligand from binding sites, with an IC50 of 2.4x10(-8) mol/l.
In plain wordsIn lab tests with human thyroid membranes, GHRP‑6 fully displaced a labeled hexarelin derivative from its binding sites.
Peptide
GHRP-6
Outcome
DecreaseDisplacement of 125I-Tyr-Ala-hexarelin (IC50)
Study
humann: not reported in source
human non-tumoral thyroid membranes
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Measurements
IC50
2.4 x10(-8) mol/l
non-tumoral thyroid membranes
Source sentences
Summary
Both peptidyl (Tyr-Ala-hexarelin, hexarelin, growth hormone releasing peptide (GHRP6) and non-peptidyl (MK 0677) GHSs completely displaced the radioligand from binding sites of non-tumoral thyroid gland, but MK 0677 was significantly less potent.
1 context sentence(design, population, supporting numbers)
Summary · context
(2.4+/- 0.3)x10(-8) mol/l for GHRP6
Report a problemFND-1075004401
12LabIn vitro (cell-free)Activity measurement
In membranes of human non-tumoral thyroid gland, hexarelin completely displaced the radioligand from binding sites, with an IC50 of 2.1x10(-8) mol/l.
In plain wordsIn lab tests with human thyroid membranes, hexarelin fully displaced a labeled hexarelin derivative from its binding sites.
Peptide
Hexarelin
Outcome
DecreaseDisplacement of 125I-Tyr-Ala-hexarelin (IC50)
Study
humann: not reported in source
human non-tumoral thyroid membranes
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Measurements
IC50
2.1 x10(-8) mol/l
non-tumoral thyroid membranes
Source sentences
Summary
Both peptidyl (Tyr-Ala-hexarelin, hexarelin, growth hormone releasing peptide (GHRP6) and non-peptidyl (MK 0677) GHSs completely displaced the radioligand from binding sites of non-tumoral thyroid gland, but MK 0677 was significantly less potent.
1 context sentence(design, population, supporting numbers)
Summary · context
(2.1+/-0.2)x10(-8) mol/l for hexarelin
Report a problemFND-1075004402

Studies that did not test the peptide alone2

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

13LabNot a test of Hexarelin aloneIn vitro (cells)Activity measurement
In NPA human follicular thyroid carcinoma cells, the hexarelin derivative Tyr-Ala-hexarelin inhibited serum-stimulated thymidine incorporation.
In plain wordsIn thyroid cancer cells, a hexarelin derivative reduced DNA synthesis stimulated by serum.
Peptide
Hexarelin
Outcome
DecreaseSerum-stimulated thymidine incorporation
Study
humann: not reported in source
NPA follicular thyroid carcinoma cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Tyr-Ala-hexarelin, GHRP6 and MK 0677 were able to inhibit serum-stimulated [(3)H]thymidine incorporation in NPA cells at concentrations close to their binding affinity.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1075004405
14LabNot a test of Hexarelin aloneIn vitro (cells)Activity measurement
In three human follicular thyroid carcinoma cell lines, the hexarelin derivative Tyr-Ala-hexarelin significantly inhibited cell proliferation at 24 h in all lines and at 96 h in NPA cells only.
In plain wordsIn thyroid cancer cell lines, a hexarelin derivative slowed cell growth, early in all three lines and late in one.
Peptide
Hexarelin
Outcome
DecreaseCell proliferation
Study
humann: not reported in source
NPA, WRO and ARO follicular thyroid carcinoma cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
These substances also caused a significant inhibition of cell proliferation, which was evident at the earliest time of treatment (24 h) in all the cell lines, and at the latest time (96 h) in NPA cells only.
1 context sentence(design, population, supporting numbers)
Summary · context
Tyr-Ala-hexarelin, GHRP6 and MK 0677 were able to inhibit serum-stimulated [(3)H]thymidine incorporation in NPA cells at concentrations close to their binding affinity.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1075004406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
14 Oct 2026, 01:46 UTC
Study data updated · source update from Europe PMC
Version 3
13 Oct 2026, 21:44 UTC
Study results updated
Version 2
13 Oct 2026, 16:31 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue.

Summary

Results from this study14

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

MeSH terms